The estimated Net Worth of David Henry Mack is at least 1.32 百万$ dollars as of 18 October 2023. Dr Mack owns over 198,407 units of Pmv Pharmaceuticals Inc stock worth over 549,454$ and over the last 6 years he sold PMVP stock worth over 0$. In addition, he makes 770,325$ as Co-Founder、 CEO、 Pres & Director at Pmv Pharmaceuticals Inc.
Dr has made over 11 trades of the Pmv Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 198,407 units of PMVP stock worth 105,156$ on 18 October 2023.
The largest trade he's ever made was exercising 198,407 units of Pmv Pharmaceuticals Inc stock on 18 October 2023 worth over 105,156$. On average, Dr trades about 22,549 units every 59 days since 2019. As of 18 October 2023 he still owns at least 363,877 units of Pmv Pharmaceuticals Inc stock.
You can see the complete history of Dr Mack stock trades at the bottom of the page.
Dr. David H. Mack Ph.D. is the Co-Founder, CEO, Pres & Director at Pmv Pharmaceuticals Inc.
As the Co-Founder、 CEO、 Pres & Director of Pmv Pharmaceuticals Inc, the total compensation of Dr D at Pmv Pharmaceuticals Inc is 770,325$. There are no executives at Pmv Pharmaceuticals Inc getting paid more.
Dr D is 59, he's been the Co-Founder、 CEO、 Pres & Director of Pmv Pharmaceuticals Inc since . There are 2 older and 3 younger executives at Pmv Pharmaceuticals Inc. The oldest executive at Pmv Pharmaceuticals Inc is Dr. Arnold J. Levine Ph.D., 81, who is the Co-Founder, Independent Director & Member of Scientific Advisory Board.
David's mailing address filed with the SEC is C/O PMV PHARMACEUTICALS, INC., ONE RESEARCH WAY, PRINCETON, NJ, 08540.
Over the last 4 years, insiders at Pmv Pharmaceuticals Inc have traded over 56,359,813$ worth of Pmv Pharmaceuticals Inc stock and bought 3,910,000 units worth 70,380,000$ . The most active insiders traders include Peter A. Thompson、Capital Management, L.P.Kol...、Thilo Schroeder. On average, Pmv Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of 130,810$. The most recent stock trade was executed by Advisors Llc Orbi Med Capit... on 22 November 2023, trading 87,786 units of PMVP stock currently worth 195,763$.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Pmv Pharmaceuticals Inc executives and other stock owners filed with the SEC include: